Collaborative & Other Agreements was Macrogenics’s largest product and service line in fiscal 2025, bringing in $87.18M of $149.50M (58%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative & Other Agreements | — | $30.55M | $119.92M | $87.18M | ||||||
| Revenue From Collaborative Agreements | $119.30M | — | — | — | ||||||
| Contract Manufacturing | $13.99M | $9.83M | $13.06M | $52.63M | ||||||
| Product Sales, Net | — | $17.94M | $16.43M | — | ||||||
| Product | $16.73M | — | — | — | ||||||
| Royalty Revenue | — | $431.00K | $561.00K | $9.69M | ||||||
| Revenue From Government Agreements | $1.92M | — | — | — | ||||||
| Revenues From License Agreements | — | — | — | — | ||||||
| Total | $151.94M | $58.75M | $149.96M | $149.50M |
Macrogenics brought in $149.50M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Macrogenics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $149.96M. Collaborative & Other Agreements was the largest at $87.18M (58.3%), ahead of Contract Manufacturing at $52.63M (35.2%) and Royalty Revenue at $9.69M (6.5%).
Compared with fiscal 2024, Royalty Revenue grew fastest, up 1,626.6% to $9.69M, while Collaborative & Other Agreements fell the most, down 27.3% to $87.18M.
Macrogenics began breaking out Collaborative & Other Agreements in fiscal 2023 and Royalty Revenue in fiscal 2023. Macrogenics stopped reporting Revenue From Collaborative Agreements ($119.30M in fiscal 2022), Product ($16.73M in fiscal 2022), Product Sales, Net ($16.43M in fiscal 2024) and one other as separate lines.
Macrogenics (MGNX) reports its revenue by product and service. In fiscal 2025, Collaborative & Other Agreements was its largest product and service line, bringing in $87.18M (58.3% of the total), followed by Contract Manufacturing at $52.63M (35.2%).
Collaborative & Other Agreements was Macrogenics' largest product and service line in fiscal 2025, bringing in $87.18M, or 58.3% of the $149.50M total across its three product and service lines.
Every figure comes from Macrogenics' annual financial filings, as reported. Each line keeps the name Macrogenics gives it, and years follow its fiscal calendar.
Macrogenics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.